Secondary metabolites are an important source of pharmaceuticals and key modulators of microbe-microbe interactions. The bacterium is part of the family of eubacteria and produces a number of biologically active secondary metabolites. In this study, we screened for novel regulators of secondary metabolites synthesized by a clinical isolate of and found mutations in a gene for an uncharacterized UmoB/IgaA family member here named Mutation of conferred a severe loss of the secondary metabolites prodigiosin and serratamolide. The mutation conferred pleiotropic phenotypes, including altered biofilm formation, highly increased capsular polysaccharide production, and loss of swimming and swarming motility. These phenotypes corresponded to transcriptional changes in ,, and Unlike other UmoB/IgaA family members, was found to be not essential for growth in , yet from , from , and an uncharacterized predicted ortholog from complemented the mutant secondary metabolite defects, suggesting highly conserved function. These data support the idea that UmoB/IgaA family proteins are functionally conserved and extend the known regulatory influence of UmoB/IgaA family proteins to the control of competition-associated secondary metabolites and biofilm formation. IgaA/UmoB family proteins are found in members of the family of bacteria, which are of environmental and public health importance. IgaA/UmoB family proteins are thought to be inner membrane proteins that report extracellular stresses to intracellular signaling pathways that respond to environmental challenge. This study introduces a new member of the IgaA/UmoB family and demonstrates a high degree of functional similarity between IgaA/UmoB family proteins. Moreover, this study extends the phenomena controlled by IgaA/UmoB family proteins to include the biosynthesis of antimicrobial secondary metabolites.